Merck & Co (NYSE-MRK) company with value and vision has been quite active in licensing in different segments in Q1 to mid Q2 of 2009.
Earlier at the beginning of this year in Jan 2009, Merck & Co signed a global strategic alliance with Galapagos (EURONEXT-GLPG) drug Discovery Company in Belgium to develop potential drug targets for obesity and diabetes. The deal potential is $251.7M. Under this term Galapagos will be responsible for discovery and preclinical development of small molecules and Merck will licence each candidate for clinical studies and commercialization on global scale.
After this deal today Merck & CO has signed a licensing deal with Medarex, Inc. (MEDX) and Massachusetts Biologic Laboratories worth $165M, wherein Merck & CO will have exclusive worldwide license agreement for CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1), an fully human Mab combination developed against Clostridium difficile toxins A and b for further treatment of C. difficile infection (CDI).
These licensing deals clearly indicate Merck's interest in biopharmaceutical market and metabolic disorder segment :)
No comments:
Post a Comment